This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Neurology				
Pain	Histone deacetylase (HDAC); glutamate decarboxylase 2 (GAD2; GAD65)	<p>Rodent studies suggest inhibiting HDACs could help treat chronic pain. In a rat model of irritant-induced chronic inflammatory pain, compared with control rats, global histone acetylation was increased and expression of GAD65 was decreased. HDAC inhibitors including Zolanza vorinostat increased GAD65 expression and reduced hyperalgesia compared with vehicle control. Next steps include identifying the specific HDAC isoforms that mediate the effect.</p> <p>Merck & Co. Inc. markets Zolanza for cutaneous T cell lymphoma (CTCL).</p> <p>SciBX 4(42); doi:10.1038/scibx.2011.1187 Published online Oct. 27, 2011</p>	Patent status undisclosed; available for licensing	<p>Zhang, Z. <i>et al. Nat. Med.</i>; published online Oct. 9, 2011; doi:10.1038/nm.2442</p> <p>Contact: Zhizhong Z. Pan, The University of Texas M.D. Anderson Cancer Center, Houston, Texas</p> <p>e-mail: zzpan@mdanderson.org</p>